liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer - a Swedish retrospective multicentre study of a clinical database
Umeå Univ, Sweden.
Umeå Univ, Sweden.
Umeå Univ, Sweden.
Umeå Univ, Sweden.
Show others and affiliations
2022 (English)In: Translational Andrology and Urology, ISSN 2223-4683, Vol. 11, no 8, p. 1105-1115Article in journal (Refereed) Published
Abstract [en]

Background: Adverse events (AEs) during neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC) are known but insufficiently reported. Clinical implications include affected cardiac, pulmonary, urinary, vascular and haematological organ systems. The main purpose was to evaluate the incidence and severity of AEs for ascertaining possible clinical significance. Further investigating possible effects of AEs on downstaging outcomes-downstaging is considered a surrogate marker for overall survival (OS).Methods: A retrospective evaluation of AEs during ongoing NAC for MIBC patients analysing individual patient data in a clinical database. We identified 687 cystectomies between 2009-2020 at four Swedish urological centres. Inclusion criteria were cT2-4aN0M0 in 261 NAC patients undergoing radical cystectomy (RC). Medical files were reviewed and AEs were assessed and graded, including detailed measurements by the Common Terminology Criteria for Adverse Events (CTCAE) v.5. Data were retrospectively analysed in SPSS statistics 27.0 with Spearman rank-order correlation coefficient and Mann-Whitney U-test (MWU).Results: A total of 251/261 patients [95% confidence interval (CI), 93-98%] experienced AEs during NAC pre-RC (mean two AEs/patient). In total, 208 (80%) patients received methotrexate, vinblastine, adriamycin (doxorubicin) and cisplatin (MVAC). In the total cohort, 200 (76.6%) received all pre-planned NAC-cycles. Most common AEs were anaemia (88.9%), thrombocytopenia (44.8%) and acute kidney injury (40.6%). Patients with prematurely terminated cycles had higher AE-grades (P=0.042 MWU). A correlation between higher AE-grades and decrease in downstaging existed, in the entire cohort (-0.133; P=0.033) and in patients undergoing all pre-planned NAC-cycles (-0.148; P=0.038). Anaemia and acute kidney injury were individually associated with decreased downstaging (-0.360, P=0.025 and -0.183, P=0.010, respectively).Conclusion: NAC in MIBC poses a significant risk for AEs before RC with clinical implications. For instance, patients terminating chemotherapy prematurely, have higher AE-grades and decreased downstaging. Further, acute kidney injury and anaemia are individually associated with decreased downstaging. We propose that early detection and prevention of AEs may increase downstaging of the primary tumour.

Place, publisher, year, edition, pages
AME Publishing Company , 2022. Vol. 11, no 8, p. 1105-1115
Keywords [en]
Bladder cancer; neoadjuvant therapy; adverse effects; cystectomy
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-187514DOI: 10.21037/tau-22-78ISI: 000834616800001Scopus ID: 2-s2.0-8513980267OAI: oai:DiVA.org:liu-187514DiVA, id: diva2:1690177
Note

Funding Agencies|Swedish Research Council [Bas-ALF/VLL RV-848051]; Cancer Research Foundation in Norrland, Umea, Sweden [CFF LP 13-2000]

Available from: 2022-08-25 Created: 2022-08-25 Last updated: 2025-11-13Bibliographically approved

Open Access in DiVA

fulltext(270 kB)176 downloads
File information
File name FULLTEXT02.pdfFile size 270 kBChecksum SHA-512
472db8f3ba29fd98d8d088fc89ec2131c079af33ff1277ed653be3cdc119fd23e4a1a549db157c9d0a1cb29ef9cbc4d9793ace5d2f9e4a2bec1607ef92473cf1
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Huge, YlvaAljabery, Firas

Search in DiVA

By author/editor
Huge, YlvaAljabery, Firas
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDepartment of Urology in Östergötland
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 177 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 126 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf